Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up
EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago.
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were among the top contributors to performance. Nebius Group, uniQure N.V., and Stevanato Group were among the top detractors from performance.
Alger Small Cap Growth Fund Q4 2025 Portfolio Update
Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Nebius Group, Wix.com Ltd., and Rezolute, Inc. were among the top detractors from performance.
Alger Mid Cap Focus Fund Q4 2025 Portfolio Update
Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Roblox Corp., Robinhood Markets, Inc., and Nebius Group were among the top detractors from performance. During the quarter, Robinhood shares detracted from performance, primarily due to a sharp decline in cryptocurrency markets.
Should You Continue to Hold EXAS Stock in Your Portfolio Now?
Exact Sciences is investing heavily in R&D and commercial capabilities to boost Cologuard adoption, but competition and macro pressures cloud the outlook.
Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
This Top Dividend King Just Became an Even Better Buy
Abbott Laboratories is acquiring Exact Sciences, in a move that will help bolster its diagnostics business. Abbott should expand the reach of Exact Sciences' key products and fuel its innovative engine.
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday
Shares of cancer screening test maker Exact Sciences Corp. (EXAS) surged Thursday after Abbott Laboratories (ABT) announced a deal to acquire the company for about $21 billion.
Exact Sciences Corporation (EXAS) M&A Call Transcript
Exact Sciences Corporation ( EXAS ) M&A Call November 20, 2025 9:00 AM EST Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, President & CEO Philip Boudreau - CFO & Executive VP of Finance Conference Call Participants Vijay Kumar - Evercore ISI Institutional Equities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Travis Steed - BofA Securities, Research Division Presentation Operator Good morning, and thank you for standing by.
Abbott to buy Exact Sciences for $21B in cancer diagnostics reach push
Abbott Laboratories (NYSE:ABT) on Thursday announced a definitive agreement to acquire cancer diagnostics company Exact Sciences (NASDAQ:EXAS) in a deal valued at approximately $21 billion. Exact Sciences, known for its noninvasive colorectal cancer screening test Cologuard and multi-cancer early detection test Cancerguard, reported projected revenue of more than $3 billion this year, with high-teens organic growth.
